tiprankstipranks
Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG
The Fly

Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG

BTIG analyst Robert Hazlett lowered the firm’s price target on Eiger BioPharmaceuticals to $9 from $48 and keeps a Buy rating on the shares. The company’s pivotal results for Lonafarnib in Hepatitis Delta were significant, though much lower than Phase 2 data, the analyst tells investors in a research note, noting that the "extra bullish veneer" is now gone from the stock. Hazlett further cites the gradual loss of viral response over time to the oral-only Lonafarnib arm beginning in week 16 through week 48, adding that the reason for this is unclear.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on EIGR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles